.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Express Scripts
Colorcon
Cantor Fitzgerald
Cipla
UBS
Citi
US Army
Farmers Insurance
Julphar

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208271

« Back to Dashboard
NDA 208271 describes RELISTOR, which is a drug marketed by Salix Pharms and Salix Pharms Inc and is included in two NDAs. It is available from one supplier. There are ten patents protecting this drug and three Paragraph IV challenges. Additional details are available on the RELISTOR profile page.

The generic ingredient in RELISTOR is methylnaltrexone bromide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the methylnaltrexone bromide profile page.

Summary for NDA: 208271

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1

Pharmacology for NDA: 208271

Ingredient-typeQuaternary Ammonium Compounds
Mechanism of ActionOpioid Antagonists

Suppliers and Packaging for NDA: 208271

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RELISTOR
methylnaltrexone bromide
TABLET;ORAL 208271 NDA Salix Pharmaceuticals, Inc. 65649-150 65649-150-06 1 BOTTLE in 1 CARTON (65649-150-06) > 6 TABLET in 1 BOTTLE
RELISTOR
methylnaltrexone bromide
TABLET;ORAL 208271 NDA Salix Pharmaceuticals, Inc. 65649-150 65649-150-60 60 TABLET in 1 BOTTLE (65649-150-60)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength150MG
Approval Date:Jul 19, 2016TE:RLD:Yes
Patent:8,524,276Patent Expiration:Mar 10, 2031Product Flag?YSubstance Flag?Delist Request?
Patent:8,956,651Patent Expiration:Mar 10, 2031Product Flag?YSubstance Flag?Delist Request?
Patent:9,314,461Patent Expiration:Mar 10, 2031Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Queensland Health
AstraZeneca
Cerilliant
Cipla
Moodys
Farmers Insurance
Boehringer Ingelheim
Covington
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot